Lung adenocarcinoma resistance to therapy with EGFR‑tyrosine kinase inhibitors is related to increased expression of cancer stem cell markers SOX2, OCT4 and NANOG

  • Authors:
    • Fang Hu
    • Changhui Li
    • Xiaoxuan Zheng
    • Hai Zhang
    • Yinchen Shen
    • Lin Zhou
    • Xiaohua Yang
    • Baohui Han
    • Xueyan Zhang
  • View Affiliations

  • Published online on: January 2, 2020     https://doi.org/10.3892/or.2019.7454
  • Pages: 727-735
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to explore the relationship between the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‑TKIs) and the expression of the cancer stem cell (CSC)‑related markers. Specimens of 72 cases of lung adenocarcinoma with significantly different therapeutic effects of the first‑generation EGFR‑TKI treatment were collected. The patients were divided into a sensitive group [progression‑free survival (PFS) longer than 26 months] and a resistant group (PFS less than 5 months) according to the efficacy of first‑line EGFR‑TKI treatment. The expression of CSC‑related markers (OCT4, SOX2, NANOG) in tumor tissues of the two groups was detected by immunohistochemical (IHC) staining, immunofluorescence and reverse transcriptase‑quantitative polymerase chain reaction (RT‑qPCR). IHC staining was quantified using H‑scores. The unpaired nonparametric t‑test was used to detect the differences in the results of IHC and RT‑qPCR analyses between the groups. The Chi‑square test was used to detect the differences in the clinical characteristics between the two groups. The t‑test revealed that the IHC H‑scores of SOX2 (P=0.003), OCT4 (P=0.036) and NANOG (P=0.032) were significantly higher in the resistant group than in the sensitive group. The results of RT‑qPCR revealed that the relative levels of SOX2 (P=0.018), OCT4 (P=0.035) and NANOG (P=0.044) were significantly higher in the resistant group than in the sensitive group. The number of male patients, patients who smoked, patients with stage IV lung adenocarcinoma disease, and patients with poor differentiation was higher in the resistant group than in the sensitive group, with statistically significant differences. The poor efficacy of first‑generation EGFR‑TKIs for lung adenocarcinoma appears to be related to the increased expression of CSC markers.
View Figures
View References

Related Articles

Journal Cover

February 2020
Volume 43 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Hu, F., Li, C., Zheng, X., Zhang, H., Shen, Y., Zhou, L. ... Zhang, X. (2020). Lung adenocarcinoma resistance to therapy with EGFR‑tyrosine kinase inhibitors is related to increased expression of cancer stem cell markers SOX2, OCT4 and NANOG. Oncology Reports, 43, 727-735. https://doi.org/10.3892/or.2019.7454
MLA
Hu, F., Li, C., Zheng, X., Zhang, H., Shen, Y., Zhou, L., Yang, X., Han, B., Zhang, X."Lung adenocarcinoma resistance to therapy with EGFR‑tyrosine kinase inhibitors is related to increased expression of cancer stem cell markers SOX2, OCT4 and NANOG". Oncology Reports 43.2 (2020): 727-735.
Chicago
Hu, F., Li, C., Zheng, X., Zhang, H., Shen, Y., Zhou, L., Yang, X., Han, B., Zhang, X."Lung adenocarcinoma resistance to therapy with EGFR‑tyrosine kinase inhibitors is related to increased expression of cancer stem cell markers SOX2, OCT4 and NANOG". Oncology Reports 43, no. 2 (2020): 727-735. https://doi.org/10.3892/or.2019.7454